Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Legend Biotech Corporation (NASDAQ: LEGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer. Legend Biotech files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together outline its financial performance, cell therapy pipeline, and key business developments.
In these filings, Legend Biotech presents unaudited interim condensed consolidated financial statements, including statements of profit or loss, financial position, changes in equity, and cash flows. Investors can review details on license revenue, collaboration revenue related to CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), research and development expenses, selling and distribution expenses, and collaboration funding arrangements. Management’s Discussion and Analysis (MD&A), often attached as exhibits to Form 6‑K, provides narrative context around revenue drivers, cost trends, and liquidity.
Filings also capture clinical and regulatory milestones. Recent 6‑Ks incorporate press releases on CARTITUDE‑1, CARTITUDE‑4, and CARTITUDE‑6 study updates, FDA and European Commission label changes for CARVYKTI, and early data from programs such as LUCAR‑G39D, LB2102, and LB1908. Additional 6‑Ks describe agreements with Janssen for component and product supply, preliminary sales figures for CARVYKTI, and participation in major scientific and investor conferences.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 6‑K and 20‑F filings, helping users quickly identify information on revenue composition, cell therapy pipeline status, collaboration structures, and risk disclosures. Real‑time ingestion of EDGAR updates ensures that new Legend Biotech filings, including any Form 6‑K related to financial results or material agreements, appear promptly.
Users can also monitor equity and compensation-related disclosures via Legend Biotech’s registration statements on Form S‑8, as referenced in its 6‑K reports, and review how these interact with share‑based compensation expenses reported in the financial statements. While Legend Biotech does not file Forms 3, 4, and 5 as a U.S. domestic issuer would, this page centralizes its available SEC reporting so investors can follow the company’s development as a global cell therapy business.
Legend Biotech Corp (LEGN) reported a Form 144 notice showing proposed sale of 1,357 American Depositary Shares through Fidelity Brokerage, listed on NASDAQ, with an aggregate market value of $46,111.81 and approximately 367,298,315 shares outstanding. The shares were acquired on 09/19/2025 through restricted stock vesting as compensation and the planned sale date is 09/23/2025. The filer also reported three prior ADS sales in June–July 2025 totaling 38,220 shares for gross proceeds of $1,505,975.55. The filing represents a routine insider sale report under Rule 144.
Legend Biotech Corp (LEGN) Form 144 summary: An insider plans to sell 474 American Depositary Shares on 09/23/2025 through Fidelity Brokerage Services. The shares were acquired on 09/19/2025 by Restricted Stock Vesting and were paid as compensation. The aggregate market value of the proposed sale is listed as $16,106.85, with the issuer's outstanding shares shown as 367,298,315. The filing also discloses a prior sale by the same person: 642 ADS sold on 07/23/2025 for $28,890.00. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Form 144 notice for Legend Biotech Corp (LEGN) reports a proposed sale of 307 American Depositary Shares (ADSs) with an aggregate market value of $10,438 and approximately 367,298,315 ADSs outstanding. The securities were acquired on 09/20/2025 through restricted stock vesting from the issuer and the stated nature of payment is compensation. The approximate date of sale listed is 09/23/2025. The filer also disclosed a prior sale on 06/24/2025 of 307 ADSs by Corazon D. Sanders for gross proceeds of $10,551.59. Several standard filing fields (issuer name, filer CIK/CCC, and contact details) appear blank in the provided content.
Legend Biotech disclosed termination and severance terms for Mr. Santos in an employment agreement. If termination triggers the shorter package, Mr. Santos would receive 12 months of base salary, the prior-year bonus if unpaid, a pro-rated portion of the target bonus for the termination year, COBRA reimbursements for up to 12 months, acceleration of any equity awards that would vest within the following 12 months (subject to any corporate performance goals), and a post-termination option exercise window extended to 12 months.
Under an enhanced package, Mr. Santos would receive 18 months of base salary, the prior-year bonus if unpaid, the full target bonus for the year of termination, COBRA reimbursements for up to 18 months, immediate full acceleration of all unvested equity awards without regard to performance, and an extended option exercise period of 18 months.
Legend Biotech reported total revenue of $255.1 million for the three months ended June 30, 2025 and $450.1 million for the six months, driven primarily by collaboration revenue (CARVYKTI) which rose to $219.7 million in Q2 and $405.3 million for H1. License revenue fell year-over-year due to timing of Janssen milestones, with license revenue of $35.3 million in Q2 versus $90.8 million a year earlier.
The company recorded a wider net loss of $125.4 million in Q2 and $226.3 million for H1; the MD&A attributes a large portion of the deterioration to unrealized foreign exchange losses (other expense of $108.1 million in Q2, $162.6 million in H1). Liquidity remains substantial with $266.6 million cash and $701.0 million time deposits (~$1.0 billion total). Management also reports CARVYKTI net trade sales of approximately $439 million and over 7,500 patients treated. Adjusted net income (non-IFRS) was $10.1 million in Q2 (ANI per share $0.03), illustrating the impact of excluding unrealized FX and certain non-cash items.
Legend Biotech Corp. (LEGN) filed a Form 144 indicating the proposed sale of 642 American Depositary Shares (ADS)—acquired through restricted-stock vesting on 03/20/2025 and valued at roughly $28,890—through Fidelity Brokerage Services. The seller plans to execute the trade on or about 07/23/2025 on NASDAQ. No other sales have occurred in the past three months, and the filing states that 367.3 million shares are outstanding.
The notice is routine: it simply pre-clears a small disposition under SEC Rule 144. The stake represents 0.00017% of shares outstanding, signalling no material change to ownership structure or to the investment thesis. The seller attests to having no undisclosed adverse information and, if relying on Rule 10b5-1, certifies plan adoption.
Legend Biotech (LEGN) filed a Form 6-K disclosing preliminary product-level revenue for its BCMA-directed CAR-T therapy, CARVYKTI. Janssen, the commercial partner, reported ≈US$439 million in net trade sales for the June-quarter 2025. Legend has not independently verified the figure and must still complete its own Q2 financial statements; the number could change once gross-to-net adjustments, profit-share calculations and auditor review are finalized.
The filing contains no P&L, cash-flow or margin data, but it does signal continued demand expansion only 2-years post-launch. Management reminds investors that revenue recognition, gross profit and royalty split will be determined during the normal close process. Forward-looking-statement language highlights usual development, regulatory and competitive risks and points users to the 2024 Form 20-F risk factors.
- The disclosed sales are informational, not yet audited.
- No guidance update or comparative growth metrics were provided.
- The filing is automatically incorporated into Legend’s existing F-3 and S-8 registration statements.
FAQ
What is the current stock price of Legend Biotech (LEGN)?
What is the market cap of Legend Biotech (LEGN)?
